Gene deletions in spinal muscular atrophy

Nanda R Rodrigues, Nicholas Owen, Kevin Talbot, Shobhna Patel, Francesco Muntoni, Jaakko Ignatius, Victor Dubowitz, Kay E Davies

Abstract
Two candidate genes (NAIP and SMN) have recently been reported for childhood onset spinal muscular atrophy (SMA). Although affected subjects show deletions of these genes, these deletions can lead to either a very mild or a severe phenotype. We have analysed a large number of clinically well defined patients, carriers, and normal controls to assess the frequency and extent of deletions encompassing both of these genes. A genotype analysis indicates that more extensive deletions are seen in the severe form of SMA than in the milder forms. In addition, 1-9% of phenotypically normal carriers are deleted for the NAIP gene; no carriers were deleted for the SMN gene. Our data suggest that deletions in both of these genes, using the currently available assays, are associated with both a severe and very mild phenotype.

Key words: spinal muscular atrophy; SMN; NAIP.

Childhood onset proximal spinal muscular atrophy (SMA) is an autosomal recessive disease in which the integrity of the motor unit is disrupted leading to widespread and inappropriate death of alpha motor neurones in the spinal cord. Affected subjects have weakness, wasting, and areflexia with variable involvement of bulbar motor nuclei. It is widely believed that muscular weakness and atrophy is secondary to this neurogenic process but there have been studies suggesting that muscle from these patients behaves abnormally in culture. This disease is an important cause of morbidity and mortality in early life, with an incidence of between 1 in 6000 and 1 in 10 000 live births. Internationally agreed diagnostic criteria and clinical classification have greatly aided genetic studies. The most severely affected patients (type I) manifest weakness between birth and 6 months, are never able to sit, and die from respiratory failure before the age of 2 years. Type II patients may sit, but never develop the ability to stand unaided; survival depends on the degree of respiratory muscle weakness. The age of onset in type III SMA is very variable, ranging from infancy to early adulthood. Disease progression is slow and these patients may remain ambulant for decades. No clues to the molecular basis of cell death in SMA have yet emerged and it is anticipated that characterisation of the disease at the molecular genetic level will open the way to its elucidation.

We, and others, have shown that all three forms of the disease map to chromosome 5q11.2–13.1,2 The disease mutation has been further refined by the identification of microsatellites that show strong linkage disequilibrium with the disease.3-13 These studies indicate a high frequency of null alleles associated with the SMA phenotype suggesting that deletions of the critical region are common in patients. Two candidate genes have been reported. The survival motor neurone gene (SMN) exists in two almost identical copies in 5q13, and the telemoric copy is deleted in 98-6% of patients.14 Three patients without deletions have point mutations. We have confirmed the SMN deletion frequency and also shown that these deletions arise de novo.15 The neuronal apoptosis inhibitory protein (NAIP) gene, which lies in the region adjacent to the SMN gene, is deleted in 45% of patients with type I SMA and 18% of those with type II and III.16 These authors reported homozygous deletions in 3/168 carriers. Pseudogenes of NAIP are present in multiple copies in the region and the deletions may be complex. A third transcript, XS2G3, mapping to the candidate region has been shown to be deleted in patients with SMA,17 but subsequently has been shown to correspond to exon 7 of NAIP in the opposite orientation. XS2G3 therefore detects the same deletions as NAIP.18

The physical maps of the SMA region presented as cloned contigs19-22 are not consistent, making the determination of the physical organisation of the candidate genes difficult.23 The presence of multicopy repetitive sequences, pseudogenes, and retrotransposon-like sequences underlies the unstable nature of this area of the genome.24-26

In view of the complexity of the region and the lack of correlation between the SMN gene deletions and the phenotype, we have attempted to construct a deletion genotype for the disease. Here we present analysis of deletions in NAIP and SMN genes in a large number of SMA patients and carriers. Our data suggest that more extensive deletions are associated with more severe disease.
Materials and methods
All patients conformed to the consensus diagnostic criteria of the International SMA Consortium. Subjects were drawn from ethnically diverse populations in the UK and included at least 70% of the known living cases of SMA ever diagnosed in Finland. Informed consent was obtained from all families participating in this study. Control DNA samples consisted of patients with haemoglobinopathies, polycystic kidney disease, and fragile X syndrome from the UK and elsewhere in Europe, and also included samples drawn from healthy blood donors from the Finnish population.
A total of 187 families with SMA were used for this analysis. Where there were multiple affected members in a family, only one subject contributed to the data set although all were analysed. In families with differences in clinical severity of the disease, the phenotype of the first born affected was used since the genotype for both phenotypes was identical. Among these families, five were of Finnish origin and two were of UK origin. In all cases it was the association of type II with type III that was observed. The association of type I SMA with the milder forms was not observed. Carrier status was assumed for parents and was determined by linkage analysis for sibs. There were 77 families with type I SMA, 69 families with type II SMA, and 41 families with type III SMA.

SSCP analysis of SMN exons 7 and 8
SSCP analysis was carried out as described by Lefebvre et al. but with the modification of using 32P labelled dATP. Genomic DNA (100–200 ng) was amplified using exon 7 (R111 and 541C770) and exon 8 (541C1120 and 541C960) specific oligonucleotide primers.

PCR analysis of NAIP exons 5 and 13
Genomic DNA (100–200 ng) was amplified with NAIP exon 5 (1863 and 1864) and exon 13 (1258 and 1343) specific oligonucleotide primers in a multiplex PCR reaction as described by Roy et al. Exon 13 is present in both functional and pseudogene copies of NAIP and therefore can be used as a positive PCR control for exon 5 which is present only in the functional NAIP gene. PCR was carried out using standard cycles with an annealing temperature of 60°C. Samples were loaded on to a 1.2% agarose gel containing ethidium bromide. Electrophoresis was carried out at 80–100 V for 1.5 hours to resolve both exon 5 and exon 13 products, which were visualised under UV fluorescence. All results showing deletions in NAIP exon 5 were repeated with exon 5 primers only, as we have found that occasionally the multiplex reaction led to inhibition of amplification of one or other exon.

Results
Analysis of deletions in the SMN gene
The analysis of SMN in 140/187 of these families has been previously reported. Absence of exons 7 and 8 specific to telomeric SMN was used to identify deletions of the SMN gene. A total of 175/187 patients (93.5%) were homozygously deleted for at least part of the telomeric copy of SMN and there was no significant difference in deletions seen in the different forms of the disease (74/77 type I, 64/69 type II, 37/41 type III). Of these patients, 88.1% had deletions of both exons 7 and 8, and 5.4% had only exon 7 deletions. None was deleted for exon 8 only. Of the patients not deleted for SMN, all but two exhibited no homozygous deletions, possessing at least one copy of NAIP and both the centromeric and telomeric forms of SMN. One patient with type I SMA showed no deletions in SMN but was deleted for NAIP exon 5 (see below). The other patient, with type II SMA, was homozygously deleted for the centromeric copies of exons 7 and 8 but retained the telomeric copies. This pattern was observed in 19/358 normal subjects, but in none of the carriers. The combination of deletions in both the centromeric and telomeric copies of SMN was never observed, suggesting that this might represent a lethal mutation. Of the 373 carriers screened, none was homozygously deleted for SMN. Of the 31 normal sibs identified by linkage studies as being non-carriers, none had any deletions. Of the 358 normal controls analysed, none showed homozygous deletions of the telomeric SMN gene.

Analysis of deletions in the NAIP gene
Exon 5 of NAIP, which is specific for the functional NAIP gene, was deleted in 51/77 of patients with type I SMA (66.2%) but only deleted in 57/69 of type II and 54/41 of type III patients (10.2% and 12.2%, respectively). This is a higher proportion of deletions than that found by Roy et al. (45% of type I patients). This increase cannot, in our data set, be accounted for by the Finnish population in which the deletion rate was 44%. Of the 373 carriers tested, seven were deleted for exon 5 of NAIP. Of these deleted carriers, 6/131 were parents of type I SMA patients, 0/111 was a parent of a type II patient, and 1/131 was a parent of a

<table>
<thead>
<tr>
<th>Deletion genotypes including SMN and NAIP</th>
<th>Genotype A</th>
<th>Genotype B</th>
<th>Genotype C</th>
<th>Genotype D</th>
<th>Genotype E</th>
<th>Genotype F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenotype</td>
<td>del</td>
<td>del</td>
<td>del</td>
<td>n</td>
<td>del</td>
<td>del</td>
</tr>
<tr>
<td>Type I</td>
<td>49/77 (63.6%)</td>
<td>23/77 (29.9%)</td>
<td>1/77 (1.3%)</td>
<td>17/77 (1.3%)</td>
<td>1/77 (1.3%)</td>
<td>2/77 (2.6%)</td>
</tr>
<tr>
<td>Type II</td>
<td>6/69 (8.7%)</td>
<td>51/69 (73.9%)</td>
<td>6/69 (8.7%)</td>
<td>1/69 (1.4%)</td>
<td>0/69 (0%)</td>
<td>5/69 (7.3%)</td>
</tr>
<tr>
<td>Type III</td>
<td>5/41 (12.2%)</td>
<td>30/41 (73.2%)</td>
<td>2/41 (4.8%)</td>
<td>0/41 (0%)</td>
<td>0/41 (0%)</td>
<td>4/41 (9.8%)</td>
</tr>
<tr>
<td>Carriers</td>
<td>0/373 (0%)</td>
<td>0/373 (0%)</td>
<td>0/373 (0%)</td>
<td>0/373 (0%)</td>
<td>7/373 (1.9%)</td>
<td>366/373 (99.1%)</td>
</tr>
</tbody>
</table>

del = deleted, n = not deleted.
Gene deletions in spinal muscular atrophy

<table>
<thead>
<tr>
<th>Genotype A</th>
<th>Genotype B</th>
<th>Genotype C</th>
<th>Genotype D</th>
<th>Genotype E</th>
<th>Genotype F</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A diagrammatic representation of the deletion genotypes described in the text. Hatched boxes represent deleted exons. Owing to the polymorphic nature of the region no particular physical orientation of SMN and NAIP is assumed.

**Type III Patient**. The 31 normal sibs showed no deletions. None of the 532 normal controls tested was deleted for NAIP.

**Combining SMN and NAIP Genes to Produce a Deletion Genotype**

The frequency of deletions of both SMN and NAIP genes in patients, carriers, and normal controls is shown in the table. These genotypes are depicted schematically in the figure. For simplicity, the order of the genes is assumed to be centromere—SMN (cen)—SMN (tel)—NAIP—telomere, as published by Lefebvre et al. This does not rule out the possibility that in some subjects, such as those with genotype D, the order could be reversed relative to the telomere, as published by Roy et al. It is not assumed that the deletions are contiguous. The deletions represented by genotype A would include telomeric SMN exon 7 and exon 8, and also NAIP (del del del). Genotype B represents a deletion including and proximal to telomeric SMN exon 7 and exon 8 only (del del n). Genotype C represents a deletion including and proximal to telomeric SMN exon 7 only (del n del). Genotype D represents a deletion in telomeric SMN exon 7 and NAIP only (del n del).

Genotype E represents a deletion for NAIP only (n n del). Genotype F has no detected deletions for telomeric SMN exon 7, SMN exon 8, or NAIP exon 5 (n n n). Since heterozygously deleted subjects cannot be determined using these assays it cannot be excluded that more extensive deletions (genotype A) exist on one of the two chromosomes of an affected subject who, for example, has genotype B or C.

Genotype A, which represents a larger deletion, has a higher incidence in type I patients compared with types II and III ($\chi^2 = 59-95$, p<0.00001). There is no statistically significant difference between the two milder forms. Genotypes B and C which represent smaller deletions are predominately found in type II and III patients. Genotype D was found in two patients and could be explained either by two deletion events or rearrangement of NAIP placing it proximal to SMN according to the map of Roy et al. Genotype E, which represents the smallest deletion, was found in one type I patient, but also in 11 carriers. Genotype F, with no detectable deletions, is more frequent in types II and III than type I.

In analyses of multiply affected sibships including those with a difference in the clinical severity of the disease, the affected sibs had identical deletions when assayed using primers for exon 5 of NAIP and exons 7 and 8 of SMN.

**Discussion**

This is an extensive analysis of the incidence of deletions in both SMN and NAIP genes in a large set of SMA patients and carriers. In the original papers, SMN gene deletions were found not to correlate with the severity of the phenotype whereas deletions in NAIP occurred more frequently in the more severely affected type I patients. The data presented here suggest that there is a very strong correlation between the extent of the deletions and the severity of the disease.

The incidence of deletions which include both SMN and NAIP genes in SMA patients was much higher in type I patients compared to type II and III patients (63-6%, 8-8%, 12-2%, respectively). Patients suffering from the milder forms of the disease showed smaller deletions which predominantly included SMN but not NAIP. There is no statistically significant difference between deletions in types II and III suggesting that these two subtypes of SMA may represent a continuum. Consistent with this observation is the fact that families with two different phenotypes rarely include subjects with type I SMA. Furthermore, while the Finnish population might seem to contain a larger than expected number of mixed phenotype families, these are the families for which we have the most accurate clinical data and it is therefore likely that the true incidence of mixed families is higher than reported here.

In two patients (type I and type II) who had deletions of SMN exon 7 and NAIP exon 5, but no deletion of SMN exon 8, it is possible that NAIP is proximal to SMN in accordance with the map published by Roy et al. or that there are two deletion events. One type I patient is not deleted for SMN but deleted for NAIP, a genotype seen in 1.9% of carriers. This patient may possess other mutations in either SMN or other genes in the region. We are currently exploring this in detail. It is of note that deletions of NAIP in carriers of SMA occur almost exclusively in parents of type I patients. The detection of NAIP deletions in carriers suggests that the non-mutated allele is probably deleted frequently. This also confirms the high degree of instability of this region. The patients who
did not show any detectable deletions of the two genes being characterised further for the presence of point mutations.

The very high frequency of deletions in the SMA gene suggests that mutations in SMA are directly involved in the disease or that the gene lies very close to the critical region. NAIP may also be involved in the pathogenesis of SMA either alone or by directly interacting with the SMA gene product. The data presented in this paper strongly suggest that homozygous deletion of a portion of the SMA gene is clearly associated with the SMA phenotype, both in the presence and absence of homozygous deletions of NAIP. However, since both SMA and NAIP genes are present in multiple copies in this region, an alternative explanation could be that the copy number of these genes is important in the manifestation of the disease. This idea is supported by the genotyping analysis using closely linked microsatellites which are also present in more than one copy in the region. There is a strong correlation between the severity of the phenotype and the number of alleles observed. The extent of deletions on each of the chromosomes could influence the amount of gene product. Thus the combination of genotype A and B on the two chromosomes of a patient could result in a more severe phenotype than genotype B and B combined. It is also important to emphasise that the current methods of analysis of both SMN and NAIP do not allow quantitation of the number of copies of these genes. While we refer to deletions occurring in SMN, it is theoretically possible that gene conversion events could account for the observed genotypes, for example, by the replacement of the telomeric version of SMN with portions of the centromeric sequence.

The assays of exon deletions used in our analyses are not sensitive enough to detect the presence or extent of the deletions or to differentiate between in frame or out of frame deletions. Thus it is possible that the deletions encompass larger isoforms of NAIP or SMN, or disrupt other genes in the region. For example, the DMD locus encodes a ubiquitously expressed small 4-8 kb transcript, but the larger 14 kb transcript expressed predominantly in muscle determines the phenotype.

In summary, the data presented here confirm that SMA is associated with a high frequency of deletions in chromosome 5q13 and indicate that the more severe phenotype is associated with more extensive deletions. If the molecular basis of SMA is to be understood it is vital that a coherent picture of the physical organisation of these genes emerges and the relationship between SMN and NAIP defined. To that end the above data will provide initial clues to the extent of deletions at the physical level and may aid the ordering of genetic loci.

We thank M A Nishit and P McShane for helpful discussions. We are also grateful to the SMA International Consortium members who have shared ideas and resources with us. We are grateful to the Medical Research Council, the Muscular Dystrophy Group of Great Britain and Northern Ireland, and the Muscular Dystrophy Group, USA for financial support. We thank the Finnish Red Cross Blood Service, and Drs P Harris, S Knight, and J Old for normal control samples.